Subscribe

Study Summaries

PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol

CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol

NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

NRG-GY012

DESKTOP Trial - Secondary Debulking Surgery

Secondary debulking surgery in recurrent ovarian cancer

PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk

Vaginal Brachytherapy vs. Pelvic External Beam Radiotherapy in Endometrial Cancer (PORTEC-2)

RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

NRG GY018: Pembrolizumab in Advanced Endometrial Cancer

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

MITO-7: Weekly chemotherapy in ovarian cancer

Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer

BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc)

GOG 281: Trametinib in recurrent low-grade serous ovarian cancer

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer.